KOREA UNITED PHARM INC
Financials
Valuation Metrics
KOREA UNITED PHARM INC's Market Cap is ₩2845B. At end of 2025 it was ₩3034B. Ranked #634 of 2,436 in KR market (top 26%), #378 of 787 on KOSPI (top 48%), #71 of 234 in Pharmaceuticals, Biotechnology & Life Sciences (top 30%) by Market Cap.
Investment Metrics(as of 2026-08-04)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 284.48B KRW | KR#634/2,436 Sec#71/234 |
| Revenue | 291.23B KRW | KR#826/2,436 Sec#38/234 |
| Net Income | 39.64B KRW | KR#429/2,436 Sec#29/234 |
| Total Assets | 563.13B KRW | KR#696/2,436 Sec#41/234 |
| Net Assets | 459.17B KRW | KR#531/2,436 Sec#32/234 |
| Employees | 936 | KR#270/2,436 Sec#21/234 |
| Value | ||
| P/E | 7.18x | KR#499/2,436 Sec#22/234 |
| P/B | 0.62x | KR#1,048/2,436 Sec#51/234 |
| PEG | 0.68x | KR#718/2,436 Sec#46/234 |
| P/S | 0.98x | KR#1,396/2,436 Sec#84/234 |
| EV/EBITDA | 5.40x | KR#258/2,436 Sec#5/234 |
| FCF Yield | 9.73% | KR#641/2,436 Sec#26/234 |
| Profitability | ||
| ROE | 8.63% | KR#623/2,436 Sec#38/234 |
| ROA | 7.04% | KR#428/2,436 Sec#33/234 |
| Op. Margin | 16.16% | KR#243/2,436 Sec#23/234 |
| Revenue Growth | 3.46% | KR#1,242/2,436 Sec#115/234 |
| Earnings Growth | 10.49% | KR#834/2,436 Sec#55/234 |
| Financial Health | ||
| Debt Ratio | 122.64% | KR#712/2,436 Sec#86/234 |
| Total Debt | 12.38B KRW | KR#1,545/2,436 Sec#139/234 |
| FCF | 27.69B KRW | KR#433/2,436 Sec#24/234 |
| Cash | 42.68B KRW | KR#832/2,436 Sec#52/234 |
| Current Ratio | 3.36x | KR#541/2,436 Sec#81/234 |
| Net Debt/EBITDA | -0.64x | KR#543/2,436 Sec#32/234 |
| Dividend | ||
| Div. Yield | 3.44% | KR#563/2,436 Sec#24/234 |
| Div. Growth | 35.56% | KR#307/2,436 Sec#14/234 |
| Performance | ||
| 1Y Return | -13.41% | KR#1,004/2,436 Sec#71/234 |
| 1M Return | 2.76% | KR#485/2,436 Sec#34/234 |
| From 52W High | -18.36% | KR#167/2,436 Sec#8/234 |
| 1Y MDD | -25.73% | KR#119/2,436 Sec#6/234 |
| Trading | ||
| Volume | 27,858 shares | KR#1,707/2,436 Sec#160/234 |
| Foreign Own. | 8.86% | KR#519/2,436 Sec#44/234 |
| Per Share | ||
| EPS | 2,431 KRW | KR#340/2,436 Sec#23/234 |
| BPS | 28,950 KRW | KR#368/2,436 Sec#26/234 |
Company Info
United Pharmaceutical, a specialized pharmaceutical manufacturer established in 1987 for the manufacture and sale of pharmaceuticals, was listed on KOSDAQ in 1999 and re-listed on KOSPI in 2007. Headquartered in Jeondong-myeon, Sejong Special Self-Governing City, the company maintains 7 affiliates including United Interpharm. It sells 18 improved new drugs and new formulation products, such as the antithrombotic treatment 'Silostan CR' (approx. 15% of sales) and the dyslipidemia treatment 'Artmac Combi-Gel' (approx. 10% of sales), to medical institutions and pharmacies nationwide.